ClinicalTrials.gg
TerminatedNCT03938545Updated Sep 22, 2022Results posted

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

A Phase 2 interventional study of RVT-1401 (Administered via subcutaneous injection) and Placebo (Administered via subcutaneous injection) in Graves' Ophthalmopathy (GO), sponsored by Immunovant Sciences GmbH. Terminated at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on premature unblinding of treatment allocations necessitated by program-wide review

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
29th of 47
65 · median 84
Started
2019
the only one that year
Phase 2
7 of 53
1 open now
Registered
12th of 53
by date
Lead sponsor
4 of 53
Immunovant Sciences GmbH

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 29th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 2, and was the 12th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG

03

Conditions studied

  • Graves' Ophthalmopathy (GO)

Browse trials for

Keywords

  • IMVT-1401
  • Graves' Orbitopathy
  • Thyroid Eye Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age.
  2. Clinical diagnosis of Graves' disease with hyperthyroidism associated with active, moderate to severe Graves' Ophthalmopathy (GO) with a Clinical Activity Score (CAS) ≥4 for the most severely affected eye at Screening and Baseline (on the 7-item scale).
  3. Onset of active GO within 9 months of screening.
  4. Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥2 millimeters (mm), moderate or severe soft tissue involvement, proptosis ≥3 mm above normal for race and gender, and/or inconstant or constant diplopia.
  5. Other, more specific inclusion criteria are defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Use of any (intravenous, oral, steroid eye drops) for the treatment of GO or other conditions within 3 weeks prior to Screening. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids which are allowed.
  2. Use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within the past 9 months prior to Baseline.
  3. Total IgG level \<6 grams per liter (g/L) at Screening.
  4. \<1500 cells per meter squared (cells/mm\^3) at Screening.
  5. Participants with decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months at Screening.
  6. Previous orbital irradiation or surgery for GO.
  7. Other, more specific exclusion criteria are defined in the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Regimen A-RVT-1401

    Regimen A= RVT-1401 680 mg weekly for 12 weeks

    Drug: RVT-1401 (Administered via subcutaneous injection)

  • Experimental
    Regimen B-RVT-1401

    Regimen B= RVT-1401 340 mg weekly for 12 weeks

    Drug: RVT-1401 (Administered via subcutaneous injection)

  • Experimental
    Regimen C-RVT-1401

    Regimen C= RVT-1401 255 mg weekly for 12 weeks

    Drug: RVT-1401 (Administered via subcutaneous injection)

  • Placebo comparator
    Placebo

    for 12 weeks

    Other: Placebo (Administered via subcutaneous injection)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Proptosis Response at Week 13

    Proptosis was assessed using an exophthalmometer. A proptosis response was defined as having at least a 2 millimeter (mm) reduction in study eye proptosis without a deterioration (at least a 2 mm increase) in the fellow eye at the same visit. The study eye was defined as the most severely affected eye at the baseline visit.

    Time frame: Baseline; Week 13

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)

    AEs - any untoward medical occurrences in a participant, temporally associated with use of a medicinal product, whether or not considered related to the product. Clinically significant changes determined by the Investigator such as vital signs, ECGs, and clinical laboratory values were also reported as AEs. TEAE is defined as an AE that starts on or after the first dose of the study drug and before 30 days after the last dose of the study drug. SAEs were defined as any untoward medical occurrences that: resulted in death; were life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; were congenital anomaly/birth defects; were important medical events that may have jeopardized the participant or may have required medical or surgical intervention; invasive or malignant cancers; and development of drug dependency or drug abuse.

    Time frame: From Baseline up to Week 20

Secondary outcomes

  1. Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13

    Binding Anti-TSHR antibody serum levels are directly associated with GO clinical features. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in binding anti-TSHR antibody levels indicated therapeutic benefit.

    Time frame: Baseline and Week 13

  2. Least Square Mean Percent Change From Baseline in Total IgG Levels

    Blood samples we collected to determine total IgG levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.

    Time frame: Baseline and Week 13

  3. Least Square Mean Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4

    Blood samples were collected to determine IgG 1,2,3 and 4 levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.

    Time frame: Baseline and Week 13

07

Results

Posted Sep 22, 2022
Limitations and caveats
The study was terminated early due to a safety finding (hypercholesterolemia).

Participant flow

Participant flow — Overall Study
MilestoneRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Started18191018
Completed1014713
Not completed8535
Withdrew: Lost to follow-up0001
Withdrew: Non-compliance with study drug0010
Withdrew: Pregnancy1000
Withdrew: Study terminated by sponsor6424
Withdrew: Withdrawal by subject0100
Withdrew: Adverse event1000

Outcome measures

PrimaryPercentage of Participants With Proptosis Response at Week 13

Proptosis was assessed using an exophthalmometer. A proptosis response was defined as having at least a 2 millimeter (mm) reduction in study eye proptosis without a deterioration (at least a 2 mm increase) in the fellow eye at the same visit. The study eye was defined as the most severely affected eye at the baseline visit.

Time frame:
Baseline; Week 13
Reported as:
Number · Percentage of participants
Percentage of Participants With Proptosis Response at Week 13
Percentage of participantsRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Percentage of Participants With Proptosis Response at Week 1330.030.808.3
Statistical analysis
  • RVT-1401 680 mg/Week vs Placebo · Cochran-Mantel-Haenszel · p = =0.1993 (p-values were obtained from a Mantel-Haenszel test stratified by smoking status at baseline comparing RVT-1401 680 mg/Week group to placebo.) · Risk difference (rd): 21.4 · 95% CI -11.3 to 54.1The risk difference was obtained from a weighted average of the difference within each stratum using Cochran Mantel-Haenszel weights.
  • RVT-1401 340 mg/Week vs Placebo · Cochran-Mantel-Haenszel · p = =0.1016 (p-values were obtained from a Mantel-Haenszel test stratified by smoking status at baseline comparing RVT-1401 340 mg/Week group to placebo.) · Risk difference (rd): 24.2 · 95% CI -4.8 to 53.2The risk difference was obtained from a weighted average of the difference within each stratum using Cochran Mantel-Haenszel weights.
  • RVT-1401 255 mg/Week vs Placebo · Cochran-Mantel-Haenszel · p = =0.2963 (p-values were obtained from a Mantel-Haenszel test stratified by smoking status at baseline comparing RVT-1401 255 mg/Week group to placebo.) · Risk difference (rd): -8.3 · 95% CI -24.0 to 7.3The risk difference was obtained from a weighted average of the difference within each stratum using Cochran Mantel-Haenszel weights.
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)

AEs - any untoward medical occurrences in a participant, temporally associated with use of a medicinal product, whether or not considered related to the product. Clinically significant changes determined by the Investigator such as vital signs, ECGs, and clinical laboratory values were also reported as AEs. TEAE is defined as an AE that starts on or after the first dose of the study drug and before 30 days after the last dose of the study drug. SAEs were defined as any untoward medical occurrences that: resulted in death; were life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; were congenital anomaly/birth defects; were important medical events that may have jeopardized the participant or may have required medical or surgical intervention; invasive or malignant cancers; and development of drug dependency or drug abuse.

Time frame:
From Baseline up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
TEAEs1616816
SAEs0010
SecondaryLeast Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13

Binding Anti-TSHR antibody serum levels are directly associated with GO clinical features. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in binding anti-TSHR antibody levels indicated therapeutic benefit.

Time frame:
Baseline and Week 13
Reported as:
Least squares mean · Percent change
Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13
Percent changeRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13-64.605 (-87.006 to -42.205)-69.663 (-89.272 to -50.054)-41.843 (-70.070 to -13.616)-4.520 (-25.580 to 16.539)
Statistical analysis
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -60.085 · 95% CI -88.857 to -31.313The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -65.143 · 95% CI -91.927 to -38.358The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = =0.0284 · Least square mean difference: -37.323 · 95% CI -70.455 to -4.190The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
SecondaryLeast Square Mean Percent Change From Baseline in Total IgG Levels

Blood samples we collected to determine total IgG levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.

Time frame:
Baseline and Week 13
Reported as:
Least squares mean · Percent change
Least Square Mean Percent Change From Baseline in Total IgG Levels
Percent changeRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Least Square Mean Percent Change From Baseline in Total IgG Levels-79.101 (-86.444 to -71.757)-65.103 (-71.687 to -58.519)-57.934 (-67.216 to -48.651)-6.098 (-12.948 to 0.753)
Statistical analysis
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -73.003 · 95% CI -82.309 to -63.697The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -59.005 · 95% CI -67.821 to -50.190The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -51.836 · 95% CI -62.660 to -41.012The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
SecondaryLeast Square Mean Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4

Blood samples were collected to determine IgG 1,2,3 and 4 levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.

Time frame:
Baseline and Week 13
Reported as:
Least squares mean · Percent change
Least Square Mean Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4
Percent changeRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
IgG1-82.040 (-90.757 to -73.323)-68.141 (-75.721 to -60.561)-67.784 (-79.273 to -56.294)-0.550 (-9.307 to 8.207)
IgG2-75.346 (-84.395 to -66.297)-53.678 (-62.077 to -45.280)-53.879 (-65.648 to -42.110)-0.481 (-9.392 to 8.431)
IgG3-88.260 (-98.901 to -77.619)-65.211 (-74.336 to -56.085)-66.182 (-79.856 to -52.508)0.503 (-9.907 to 10.914)
IgG4-68.559 (-77.456 to -59.663)-55.391 (-63.131 to -47.651)-52.916 (-64.774 to -41.059)0.163 (-9.167 to 9.493)
Statistical analysis
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -81.490 · 95% CI -93.203 to -69.777The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -67.591 · 95% CI -78.562 to -56.620The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -67.233 · 95% CI -81.073 to -53.394The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -74.865 · 95% CI -86.898 to -62.832The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -53.198 · 95% CI -64.799 to -41.596The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -53.398 · 95% CI -67.552 to -39.245The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -88.764 · 95% CI -103.039 to -74.489The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -65.714 · 95% CI -78.742 to -52.686The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -66.685 · 95% CI -83.157 to -50.214The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 680 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -68.722 · 95% CI -80.877 to -56.568The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 340 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -55.554 · 95% CI -67.182 to -43.926The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.
  • RVT-1401 255 mg/Week vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: -53.079 · 95% CI -67.948 to -38.210The model included baseline value of the corresponding parameter, smoking stratum, and treatment group as covariates.

Adverse events

Collected over From Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RVT-1401 680 mg/Week0/18 (0%)0/18 (0%)16/18 (88.9%)
RVT-1401 340 mg/Week0/19 (0%)0/19 (0%)16/19 (84.2%)
RVT-1401 255 mg/Week0/10 (0%)1/10 (10%)8/10 (80%)
Placebo0/18 (0%)0/18 (0%)16/18 (88.9%)
Most frequent serious events
Most frequent serious events
EventRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Optic neuropathyEye disorders0/180/191/100/18
Most frequent other events
Showing 10 of 81
Most frequent other events
EventRVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlacebo
Injection site erythemaGeneral disorders9/189/193/103/18
Oedema peripheralGeneral disorders5/180/190/100/18
LethargyNervous system disorders2/185/191/104/18
NauseaGastrointestinal disorders0/184/190/102/18
Injection site swellingGeneral disorders1/184/191/101/18
Injection site painGeneral disorders1/183/190/100/18
Muscle spasmsMusculoskeletal and connective tissue disorders1/183/190/100/18
Intraocular pressure increasedInvestigations2/180/190/102/18
ArthralgiaMusculoskeletal and connective tissue disorders0/180/191/102/18
Abdominal pain upperGastrointestinal disorders1/182/190/100/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
Mean46.6 ± 9.0352.4 ± 8.0844.3 ± 12.6146.1 ± 12.4747.8 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
Female151381450
Male362415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
Hispanic or Latino12003
Not Hispanic or Latino1717101862
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1718101863
More than one race00000
Unknown or Not Reported11002
Mean Proptosis
Mean Proptosis(Millimeters (mm))RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
Mean22.7 ± 3.1023.0 ± 3.9722.3 ± 2.9522.7 ± 2.7022.72 ± 3.19
Mean Clinical Activity Score (CAS)
Mean Clinical Activity Score (CAS)(Units on a scale)RVT-1401 680 mg/WeekRVT-1401 340 mg/WeekRVT-1401 255 mg/WeekPlaceboTotal
Mean4.8 ± 0.865.1 ± 0.944.9 ± 0.995.2 ± 1.045.0 ± 0.94
08

Study locations

25 sites
  • Multispecialty Aesthetic Clinical Research Organziation (MACRO)
    Beverly Hills, California 90212, United States
  • Doheny Eye Center UCLA
    Pasadena, California 91105, United States
  • University of Miami Miller School of Medicine Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • University of Iowa Hospitals & Clinics - Eye Clinic
    Iowa City, Iowa 52242, United States
  • University of Michigan - Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center
    Saint Louis, Missouri 63146, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill
    Portland, Oregon 97239, United States
  • Eye Wellness Center
    Houston, Texas 77005, United States
  • Eyelid Center of Utah
    Salt Lake City, Utah 84102, United States
  • West Virginia University Eye Institute
    Morgantown, West Virginia 26506, United States
  • University of British Columbia
    Vancouver, British Columbia V5Z-1M9, Canada
  • Toronto Retina Institute
    North York, Ontario M3C 0G9, Canada
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Ophthalmology University Center- Hôpital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Universitat Duisburg-Essen
    Duisburg, 47057, Germany
  • Orbitazentrum Frankfurt
    Frankfurt am Main, 60318, Germany
  • Universitätsmedizin Mainz
    Mainz, 55131, Germany
  • ARNAS Garibaldi, Presidio di Nesima
    Palermo, Catania 95122, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana
    Pisa, 56124, Italy
  • Hospital Universitari de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Centro de Oftalmologia Barraquer
    Barcelona, 08021, Spain
  • University Hospital Ramon y Cajal
    Madrid, 28034, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Feb 2021, 18 months.

Results were first posted in Sep 2022, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
May 6, 2019
StartActual
Jul 23, 2019
Primary completionActual
Feb 2, 2021
CompletionActual
Apr 15, 2021
Results first posted
Sep 22, 2022
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03938545
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
May 6, 2019
Start date
Jul 23, 2019
Primary completion
Feb 2, 2021
Completion
Apr 15, 2021
Results posted
Sep 22, 2022
Last update
Sep 22, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion